Tbg Diagnostics Limited (TDL:ASX)

27.0¢

right-arrow Created with Sketch. 0 (0%)
Last trade 21.10pm 27/09/2020 20mins delayed

Company Overview

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

TDL in the news

TBG Diagnostics’ (TDL) subsidiary, TBG Biotechnology, has received U.S. Food and Drug…

TDL in the news

TBG Diagnostics’ (TDL) subsidiary, TBG Biotechnology, has received the U.S. Food and…
TBG Diagnostics (TDL) has announced its subsidiary, TBG Biotechnology, has received CE…
TBG Diagnostics (TDL) has reported that its investee company, TBG Biotechnology Xiamen…
TBG Diagnostics (TDL) has reported that its investee company, TBG Biotechnology Xiamen…